People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elcelyx Therapeutics, Inc. | — | Biotechnology | Series B | $73.4M | $18.9M | 2010 |
| Calithera Biosciences, Inc. | — | Biotechnology | Series B | $67.1M | $635.0M | 2014 |
| Catalyst Biosciences Inc | — | Biotechnology | Series C | $65.3M | $77.4M | 2013 |
| Stemgent, Inc. | — | Biotechnology | Series A | $37.9M | $408.5M | 2009 |
| Adastra Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $28.8M | $69.7M | 2012 |
| Globeimmune Inc | — | Pharmaceuticals | Series B | $28.0M | $71.4M | 2013 |
Ralph E. Christoffersen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ralph E. Christoffersen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ralph Christoffersen | 4 | 5 |
| Augustine Lawlor | 3 | 8 |
| Augustine E. Lawlor | 2 | 6 |
| Asish Xavier | 1 | 18 |
| Michael Powell | 1 | 14 |
| S Edward Torres | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| Jean George | 1 | 6 |
| Bosun Hau | 1 | 6 |
| Paul Mieyal | 1 | 5 |
| Jeff Himawan | 1 | 4 |
| James Wells | 1 | 4 |
| Nassim Usman | 1 | 4 |
| J. William Freytag | 1 | 4 |
| Paul A. Mieyal | 1 | 4 |
| Harold R. Werner | 1 | 4 |
| Jim Glasheen | 1 | 3 |
| Dan J. Mitchell | 1 | 3 |
| Thomas M. Estok | 1 | 3 |
| RICHARD J. BARRY | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.